+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

T-Cell Lymphoma Market 2019-2025

  • ID: 5145110
  • Report
  • September 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • Amgen Inc.
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Gilead Sciences, Inc.
  • Medivir AB
  • Novartis International AG
Global T-Cell Lymphoma Market Size, Share & Trends Analysis Report by Type (Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult T-Cell Lymphoma, and Others) by Treatment Type (Radiotherapy, Chemotherapy, Targeted Therapy, Gene Therapy, and Others) Forecast, 2019-2025.

The global T-Cell Lymphoma market is estimated to grow significantly during the forecast period. Lymphoma or blood cancer occurs when cells of the immune system, known as lymphocytes grow enormously and uncontrollably in the body. The primary factor driving the growth of the market include increasing incidences of lymphoma cancer in patients owing to exposure to harmful radiations. In addition, the investments in R&D of cancer treatment by the governments and private organizations, increase in the number of T-cells lymphoma-specific therapies, and reduction in the cost of treatment. However, the higher costs of the treatment may hamper the growth of the market during the forecast period.

The global T-Cell Lymphoma market is segmented on the basis of type and treatment type. Based on the type, the market is segmented into peripheral T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, and others. Based on the treatment type, the market is segmented into radiotherapy, chemotherapy, therapy, and others such as targeted therapy. Chemotherapy is estimated to contribute a prominent share in the market.

Geographically, the study of the global -Cell Lymphoma market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global -Cell Lymphoma market during the forecast period.

Further, Johnson & Johnson Services Inc., Novartis International AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Amgen Inc., Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Genmab A/S, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and others are some of the prominent players operating in the global T-Cell Lymphoma market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players to sustain in the highly competitive market.

Research Methodology

The market study of the global T-Cell Lymphoma market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for T-Cell Lymphoma market players, pharmaceutical and medical device companies, industry associations and experts, research institutes, government organizations, regulatory bodies, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation

1. Global T-Cell Lymphoma Market Research and Analysis by Type
2. Global T-Cell Lymphoma Market Research and Analysis by Treatment Type

The Report Covers
  • Comprehensive research methodology of the global T-Cell Lymphoma market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global T-Cell Lymphoma market.
  • Insights about market determinants which are stimulating the global T-Cell Lymphoma market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Gilead Sciences, Inc.
  • Medivir AB
  • Novartis International AG
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Key Strategy Analysis
3.2. Key Company Analysis
3.2.1. Spectrum Pharmaceuticals, Inc.
3.2.1.1. Overview
3.2.1.2. Financial Analysis
3.2.1.3. SWOT Analysis
3.2.1.4. Recent Developments
3.2.2. Johnson & Johnson Services Inc.
3.2.2.1. Overview
3.2.2.2. Financial Analysis
3.2.2.3. SWOT Analysis
3.2.2.4. Recent Developments
3.2.3. Seattle Genetics Inc.
3.2.3.1. Overview
3.2.3.2. Financial Analysis
3.2.3.3. SWOT Analysis
3.2.3.4. Recent Developments
3.2.4. Autolus Therapeutics PLC
3.2.4.1. Overview
3.2.4.2. Financial Analysis
3.2.4.3. SWOT Analysis
3.2.4.4. Recent Developments
3.2.5. Novartis International AG
3.2.5.1. Overview
3.2.5.2. Financial Analysis
3.2.5.3. SWOT Analysis
3.2.5.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. Global T-Cell Lymphoma Market by Type
5.1.1. Peripheral T-cell Lymphoma
5.1.2. Cutaneous T-cell Lymphoma
5.1.3. Anaplastic Large Cell Lymphoma
5.1.4. Angioimmunoblastic T-cell Lymphoma
5.1.5. Others (Adult T-Cell Lymphoma)
5.2. Global T-Cell Lymphoma Market by Treatment Type
5.2.1. Radiotherapy
5.2.2. Chemotherapy
5.2.3. Others

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. Actelion Pharmaceuticals Ltd.
7.2. Amgen Inc.
7.3. Autolus Therapeutics Plc
7.4. BioCryst Pharmaceuticals Inc.
7.5. Bristol-Myers Squibb Co.
7.6. Celgene Corp.
7.7. Cellerant Therapeutics, Inc.
7.8. Eisai Co. Ltd.
7.9. F. Hoffmann-La Roche Ltd.
7.10. Gilead Sciences, Inc.
7.11. GlaxoSmithKline PLC
7.12. Johnson & Johnson Services Inc.
7.13. Medivir AB
7.14. Merck & Co. Inc.
7.15. Novartis International AG
7.16. Pfizer Inc.
7.17. Sanofi SA
7.18. Seattle Genetics Inc.
7.19. Sorrento Therapeutics, Inc.
7.20. Spectrum Pharmaceuticals, Inc.
7.21. Takeda Pharmaceutical Co. Ltd.

LIST OF TABLES
1. GLOBAL T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
2. GLOBAL PERIPHERAL T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
3. GLOBAL CUTANEOUS T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
4. GLOBAL ANAPLASTIC LARGE CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
5. GLOBAL ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
6. GLOBAL OTHER T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
7. GLOBAL T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
8. GLOBAL RADIOTHERAPY FOR T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
9. GLOBAL CHEMOTHERAPY FOR T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
10. GLOBAL OTHER THERAPY FOR T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
11. GLOBAL T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
12. NORTH AMERICAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
13. NORTH AMERICAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
14. NORTH AMERICAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
15. EUROPEAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
16. EUROPEAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
17. EUROPEAN T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
18. ASIA-PACIFIC T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
19. ASIA-PACIFIC T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
20. ASIA-PACIFIC T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)
21. REST OF THE WORLD T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
22. REST OF THE WORLD T-CELL LYMPHOMA MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2018-2025 ($ MILLION)

LIST OF FIGURES
1. GLOBAL T-CELL LYMPHOMA MARKET SHARE BY TYPE, 2018 VS 2025 (%)
2. GLOBAL T-CELL LYMPHOMA MARKET SHARE BY TREATMENT TYPE, 2018 VS 2025 (%)
3. GLOBAL T-CELL LYMPHOMA MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
4. US T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
5. CANADA T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
6. UK T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
7. FRANCE T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
8. GERMANY T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
9. ITALY T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
10. SPAIN T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
11. ROE T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
12. INDIA T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
13. CHINA T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
14. JAPAN T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
15. REST OF ASIA-PACIFIC T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF THE WORLD T-CELL LYMPHOMA MARKET SIZE, 2018-2025 ($ MILLION)
Note: Product cover images may vary from those shown
  • Actelion Pharmaceuticals Ltd.
  • Amgen Inc.
  • Autolus Therapeutics Plc
  • BioCryst Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • Cellerant Therapeutics, Inc.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Medivir AB
  • Merck & Co. Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Seattle Genetics Inc.
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll